Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Home/The Filing Wire/SANGAMO THERAPEUTICS INC/ SCHEDULE 13G/A

SEC Filing · SCHEDULE 13G/A

SANGAMO THERAPEUTICS INC

SGMOQOTCEQUITYCurrent

SEC Filing

Filed Aug 14, 2026Accepted Aug 14, 2026, 10:26 AM EDTCIK 1001233Accession 0001172661-26-003615
View company →Permanent SEC source ↗
Share

Company context

Sangamo Therapeutics is a genomic medicine company that pioneered the development of zinc finger and capsid delivery technologies to address serious neurological and rare diseases. The Company is currently operating under court supervision in Chapter 11. To learn more, visit www.sangamo.com.

Current securities

SGMOQOTC · EQUITY · Current

Recent company filings

  1. Bankruptcy or Receivership · Completion of Acquisition or Disposition of AssetsSep 21, 2026
  2. Bankruptcy or Receivership · Completion of Acquisition or Disposition of Assets · Regulation FD DisclosureSep 8, 2026
  3. Entry into a Material Definitive Agreement · Bankruptcy or ReceivershipAug 28, 2026
  4. NT 10-Q filingAug 17, 2026
  5. Other EventsAug 13, 2026

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗